Oxidative versus Recovery Therapeutics in Type 2 Diabetes Mellitus: An Immunometabolic Perspective

Abstract

Type 2 diabetes (T2DM) is a complex immunometabolic disorder characterized by insulin resistance, pancreatic β-cell dysfunction, oxidative stress, and persistent low-grade inflammation. Redox imbalance is exacerbated by advanced glycation, lipotoxicity, and endoplasmic reticulum stress, whereas persistent nutritional excess promotes the generation of mitochondrial and non-mitochondrial reactive oxygen species (ROS). Metabolic stress is linked to cytokine generation and tissue damage by ROS-sensitive pathways, including NF-κB, JNK, and the NLRP3 inflammasome. The conceptual distinction between recovery therapies, which aim to maintain or restore cellular and tissue function, and oxidative treatments, which primarily minimize abnormal redox signaling and inflammatory damage, is developed in this study. Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone illustrate the overlap between these categories, whereas alpha-lipoic acid, curcumin, berberine, and other targeted phytochemicals exemplify more direct redox interventions. Extracellular vesicles, mitochondrial quality control, and mesenchymal stromal cells are examples of regenerative techniques that are still under research. Although there may be complementary immunometabolic benefits from nutritional treatments such as flaxseed, chia, and medicinal plants such as turmeric, berberine-containing botanicals, and cinnamon, their evidence base should be evaluated more cautiously than that of recognized pharmacotherapies. We suggest that progressive regulation of oxidative damage, immune activation, and tissue healing should replace a single-endpoint antioxidant paradigm in lasting therapy.